RT Journal Article
T1 Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
A1 Martínez Cuadrón, David
A1 Serrano, Josefina
A1 Mariz, José
A1 Gil, Cristina
A1 Tormo, Mar
A1 Martínez Sánchez, María Del Pilar
A1 Rodríguez Arbolí, Eduardo
A1 García Boyero, Raimundo
A1 Rodríguez Medina, Carlos
A1 Martínez Chamorro, Carmen
A1 Polo, Marta
A1 Bergua, Juan
A1 Aguiar, Eliana
A1 Amigo, María
A1 Herrera, Pilar
A1 Alonso Domínguez, Juan Manuel
A1 Bernal, Teresa
A1 Espadana, Ana
A1 Sayas, María
A1 Algarra, Lorenzo
A1 Vidriales, María B.
A1 Vasconcelos, Graça
A1 Vives, Susana
A1 Pérez Encinas, Manuel
A1 López, Aurelio
A1 Noriega Concepción, Víctor
A1 García Fortes, María
A1 Chillón, María
A1 Rodríguez Gutiérrez, Juan
A1 Calasanz, María
A1 Labrador, Jorge
A1 López, Juan
A1 Boluda, Blanca
A1 Rodríguez Veiga, Rebeca
A1 Martínez López, Joaquín
A1 Barragán, Eva
A1 Sanz, Miguel
A1 Montesinos, Pau
AB This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.
PB MDPI
SN 2072-6694
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/72154
UL https://hdl.handle.net/20.500.14352/72154
LA eng
NO Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
DS Docta Complutense
RD 9 abr 2025